Actuate Therapeutics Bolsa (NASDAQ: ACTU)

Últimas noticias sobre Actuate Therapeutics (NASDAQ:ACTU) Bolsa

Actuate Therapeutics

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics Inc

Earnings

News

Universal Health Realty Q1 EPS $0.34 Down From $0.38 YoY, Sales $24.55M Down From $25.14M YoY; FFO $0.86

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 45.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed up 18.52% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 15.38% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 11.48% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed up 9.59% at $0.45</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 8.87% at $0.20</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 7.41% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 7.01% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 4.33% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 4.17% at $0.00</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 16.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 12.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 9.47% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 7.61% at $0.78</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 7.41% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed down 7.29% at $0.88</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 7.24% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 6.81% at $0.24</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed down 5.97% at $5.57</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 5.82% at $7.50</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 4.96% at $1.34</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 4.25% at $4.28</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 3.53% at $0.00</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BBRRF

BLGVF

BLOZF

CBDY

CLSH

CNBX

CNTMF

CRBP

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CWBHF

CXXIF

FFNTF

FUAPF

GTBIF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

MRMD

NWVCF

RMHB

SOLCF

TCNNF

YCBD

Marijuana Stock Movers For April 28, 2025

Cadence Design Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) reported first-quarter financial results Monday after the close. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/04/b45051800/cadence-reports-first-quarter-2025-financial-results">of the report</a>.
Q1 Earnings: Cadence Design Systems reported first-quarter revenue of $1.24 billion, in line with analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a>. Total revenue was up 23% compared to the first quarter of 2024, driven by &#8220;broad-based strength&#8221; across all of the company&#8217;s businesses.
The company reported first-quarter adjusted earnings of $1.57 per share, beating analyst estimates of $1.49 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Business highlights include semiconductor IP growth of 40% year-over-year in the first quarter and more than 50% growth in system design and analysis revenue.
Backlog totaled $6.4 billion at quarter&#8217;s end, with current remaining performance obligations of $3.2 billion. Cadence Design Systems ended the quarter with approximately $2.78 billion in cash and cash equivalents.
&#8220;Cadence delivered excellent results for the first quarter of 2025 with robust ongoing customer demand for our innovative technologies driving 23% revenue growth and 34% non-GAAP EPS growth year-over-year,&#8221; said Anirudh Devgan, president and CEO of Cadence Design Systems.
&#8220;We haven&#8217;t seen any change in customers&#8217; behavior at this time, as they continue investing in R&amp;D for their next-gen designs. Our resilient software business model, strong backlog, and AI-driven product innovations, position us well in navigating today&#8217;s dynamic macro environment.&#8221;
Guidance: Cadence Design Systems raised its full-year 2025 outlook. The company sees full-year revenue in the range of $5.15 billion to $5.23 billion, up from previous guidance of $5.14 billion to $5.22 billion. <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates currently call for full-year revenue of $5.19 billion. The company anticipates full-year adjusted earnings of $6.73 to $6.83 per share, up from prior guidance of $6.65 to $6.75 per share. Analysts are forecasting full year-earnings of $6.71 per share.
Cadence Design Systems executives will hold a conference call at 5 p.m. ET to further discuss the quarter with investors and analysts. 
CDNS Price Action: <a href="http://benzinga.com/quote/cdns" target="_blank" rel="noreferrer noopener">Cadence Design Systems shares</a> were down 1.53% after hours, trading at $281.38 at the time of publication Monday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45046046/apple-q2-will-be-better-than-feared-analyst-says-iphone-company-has-proven-track-record">Apple Q2 Will Be &#8216;Better-Than-Feared&#8217;: Analyst Says iPhone Company Has &#8216;Proven Track Record&#8217;</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/JHVEPhoto">JHVEPhoto</a>/Shutterstock.

Guidance

Tech

CDNS

Cadence Design Systems Q1 Earnings: Revenue In Line, EPS Beat, Raised Guidance — 'We Haven't Seen Any Change In Customers' Behavior'

Two Harbors Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>) reported quarterly earnings of $0.24 per share which missed the analyst consensus estimate of $0.40 by 40 percent. This is a 380 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $(20.33 million) which beat the analyst consensus estimate of $(30.87 million) by 34.13 percent. This is a 51.84 percent increase over sales of $(42.22 million) the same period last year.

Earnings Beats

Earnings Misses

Two Harbors Inv Q1 Adj. EPS $0.24 Misses $0.40 Estimate, Sales $(20.33M) Beat $(30.87M) Estimate

Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) sees Q2 sales of $158.000 million-$176.000 million vs $165.75 million analyst estimate.

RMBS

Rambus Sees Q2 Licensing billings $64M - $70M, Product revenue $77M - $83M, Contract and other revenue $17M - $23M and also expects royalty revenue to be between $67 million and $73 million

WIIM

BYON

Beyond shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

Piedmont Office Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PDM#NYSE">PDM</a>) affirms FY2025 FFO guidance from $1.38-$1.44 to $1.38-$1.44 vs $1.42 analyst estimate..

Piedmont Office Realty Affirms FY2025 FFO Guidance of $1.38-$1.44 vs $1.42 Est

Seaboard (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SEB#AMEX">SEB</a>) reported quarterly earnings of $32.95 per share. This is a 45.41 percent increase over earnings of $22.66 per share from the same period last year. The company reported $2.32 billion in sales this quarter. This is a 5.71 percent increase over sales of $2.19 billion the same period last year.

Seaboard Q1 EPS $32.95 Up From $22.66 YoY, Sales $2.32B Up From $2.19B YoY

Powell Max (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMAX#NASDAQ">PMAX</a>) reported quarterly losses of $(0.18) per share. The company reported $4.69 million in sales this quarter.

PMAX

Powell Max FY EPS $(0.18), Sales $4.69M

Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) lowers FY2025 FFO guidance from $9.23-$9.43 to $9.16-$9.36 vs $9.27 analyst estimate..

Alexandria Real Estate Lowers FY2025 FFO Guidance from $9.23-$9.43 to $9.16-$9.36 vs $9.27 Est

Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) Q2 expected to be below $0.04 vs $0.09 Est. sees Q2 sales of $120.000 million-$135.000 million vs $137.59 million analyst estimate.

HLIT

Harmonic Q2  expected to be below $0.04 vs $0.09 Est; Sees Q2 Sales $120.000M-$135.000M vs $137.59M Est

Ebang Intl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBON#NASDAQ">EBON</a>) reported quarterly losses of $(3.22) per share. This is a 45.05 percent increase over losses of $(5.86) per share from the same period last year. The company reported $5.87 million in sales this quarter. This is a 20.88 percent increase over sales of $4.86 million the same period last year.

EBON

Ebang Intl Hldgs FY EPS $(3.22) Up From $(5.86) YoY, Sales $5.87M Up From $4.86M YoY

Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) could show how the macroeconomic environment is affecting consumers who buy their daily coffee at restaurants or opt to brew it at home when the company reports its second-quarter financial results on Thursday after the <a href="https://www.benzinga.com/earnings">market close.</a>
Earnings Estimates: Analysts expect Starbucks to report second-quarter revenue of $8.86 billion, up from $8.56 billion in the same quarter last year, according to data <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428">from Benzinga Pro.</a>
The company beat Street consensus estimates in <a href="https://www.benzinga.com/general/restaurants/25/01/43288533/starbucks-q1-earnings-revenue-beat-eps-beat-memberships-up-1-positive-response-to-turnaround-efforts">the first quarter</a> while missing estimates in four of the last five quarters. Over the last 10 quarters, the coffee company has missed analyst estimates six times.
Analysts expect the company to report second-quarter earnings per share of 50 cents, down from 68 cents per share in last year's second quarter.
The company beat first-quarter earnings per share estimates while missing estimates in three of the last five quarters. Over the last 10 quarters, the coffee company has beaten analyst estimates five times.
Read Also: <a href="https://www.benzinga.com/trading-ideas/technicals/25/04/45041645/coke-vs-coffee-can-coca-cola-stay-fizzy-starbucks-rebound-after-earnings">Coke Vs. Coffee: Can Coca-Cola Stay Fizzy? Starbucks&#8217; Rebound After Earnings?</a>
What Analysts Are Saying: Many analysts have been lowering price targets on Starbucks ahead of the quarterly financial results.
Other analysts are mixed with some upgrades and downgrades ahead of the report.
Jefferies analyst Andy Barish <a href="https://www.benzinga.com/general/restaurants/25/04/44747022/brewing-caution-jefferies-warms-up-to-starbucks-with-tepid-upgrade">recently upgraded Starbucks </a>stock from Underperform to Hold with a price target of $76.
The analyst said Starbucks could have a modest earnings rebound over the next two years with a new CFO and a lack of formal guidance. Barish said the rebound could take time to show results.
A "Back to Starbucks" initiative and new CEO Brian Niccol could lead to investments in new areas as the company works to achieve a goal of four-minute service for customers.
While Barish said the recovery could take longer than many investors anticipate, the analyst said the stock valuation looks reasonable, trading at around 20 times estimated fiscal 2027 earnings.
Here are other recent <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">analyst ratings on Starbucks </a>and their price targets:
<ul>
<li>Barclays: Maintained Overweight rating, lowered price target from $124 to $106</li>
<li>Wells Fargo: Maintained Overweight rating, lowered price target from $125 to $100</li>
<li>Stifel: Maintained Buy rating, lowered price target from $114 to $103</li>
<li>Citigroup: Maintained Neutral rating, lowered price target from $100 to $88.</li>
<li>Baird: Downgraded from Outperform to Neutral, lowered the price target from $114 to $85</li>
</ul>
Key Items to Watch: One of the key items to watch for Starbuck&#8217;s financial results will likely be store traffic and same-store sales. On February 10, Starbucks<a href="https://www.benzinga.com/general/restaurants/25/02/43798707/starbucks-makes-big-bet-on-day-after-super-bowl-data-shows-the-move-may-have-won"> offered free coffee</a> to reward members for "Starbucks Monday."
The date, which came the day after the Super Bowl, saw foot traffic spike 26% over the average Monday, according to data from Placer.ai. The promotion likely led to increased store spending, as some may have offset the free coffee by spending on other food and beverage items.
More importantly, the promotion likely led to an increase in the company's loyalty program membership, which could be highlighted in the current quarter.
Another Placer.ai <a href="https://www.placer.ai/anchor/articles/dutch-bros-gains-but-starbucks-holds-top-spot">survey </a>showed that coffee chains are seeing increased visit rates in the first calendar quarter of 2025. The bad news is that Starbucks saw a 0.9% drop in visits during the time period, according to the report.
Smaller coffee chains like 7 Brew Coffee, Scooter's Coffee and Dutch Bros Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) could be eating market share from Starbucks, according to the report. Publicly traded Dutch Bros saw a 13.4% year-over-year gain in visit rates in the first calendar quarter, which could be good news ahead of their first-quarter financial results, due on May 7.
Starbucks had declines in comparable stores across North America, international locations and China in the first fiscal quarter. Analysts and investors will be closely monitoring to see if sales improved in any of the regions.
Analysts and investors will also be hoping for an update on reports the coffee chain is exploring a sale of its China business. An update on the process could send shares higher as analysts grasp the valuation metric and interested parties become aware of the segment.
SBUX Price Action: Starbucks stock is up 0.2% to $83.94 on Monday versus a 52-week trading range of $71.55 to $117.46. Starbucks stock is down 9.0% year-to-date in 2025 and down 5% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/asia/25/03/44486235/chinas-milk-tea-chain-chagee-files-for-nasdaq-ipo-under-cha-taking-on-starbucks-in-growing-market">China&#8217;s Milk Tea Chain Chagee Files For Nasdaq IPO Under &#8216;CHA,&#8217; Taking On Starbucks In Growing Market</a></li>
</ul>
Photo: Shutterstock

Previews

Restaurants

Trading Ideas

BROS

SBUX

Starbucks Q2 Earnings Preview: Will Results Show Turnaround Progress?

Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) Q2 expected to be more than $(0.55) vs $(0.08) Est. sees Q2 sales of $85.000 million-$105.000 million vs $111.20 million analyst estimate.

Medifast Q2  expected to be more than $(0.55) vs $(0.08) Est; Sees Q2 Sales $85.000M-$105.000M vs $111.20M Est

Portillo's Inc. ("Portillo's" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLO#NASDAQ">PTLO</a>), the fast-casual restaurant concept known for its menu of Chicago-style favorites, today announced that it has entered into a cooperation agreement with Engaged Capital, LLC ("Engaged Capital"). As part of the cooperation agreement, Portillo's and Engaged Capital will cooperate to identify a new director with recent and relevant restaurant operating experience to be appointed to the Portillo's Board of Directors.

PTLO

Portillo's Enters Into Cooperation Agreement With Engaged Capital To Further Strengthen Board

UCTT

Ultra Clean Holdings shares are trading lower after the company reported worse-than-expected Q1 financial result and issued Q2 guidance below estimates.

Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) shares traded lower Monday. AMD, along with the semiconductor industry, may have reacted to reports suggesting Huawei developed an artificial intelligence (AI) chip to challenge NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
What To Know: According to the <a href="https://www.wsj.com/tech/chinas-huawei-develops-new-ai-chip-seeking-to-match-nvidia-8166f606">Wall Street Journal</a>, the Chinese technology company developed the Ascend 910D and began approaching other technology companies about testing its capabilities.
Huawei hopes that its Ascend AI processors will be more powerful than the Nvidia H100 chip.
The Ascend 910D utilizes new packaging technologies to integrate more silicon dies together in order to boost performance. However, the chip is reportedly less power-efficient compared to the H100, according to people familiar with the matter.
AMD, along with the semiconductor industry, may have traded lower as investors assess the effects of the increased competition from Huawei on the industry. A stronger Huawei could add pressure to American chipmakers by intensifying global competition in the AI and semiconductor markets.
AMD Price Action: AMD stock closed 0.26% lower at $96.39, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
See Also: • <a href="https://www.benzinga.com/25/04/45049512/eastmans-china-risk-jp-morgan-warns-trade-tensions-weighing-on-eastmans-growth-prospects">JP Morgan Cautions Trade Tensions Are Weighing On Eastman Chemical Growth Prospects</a>

Image: This illustration was generated using artificial intelligence via Midjourney.

NVDA

What's Going On With Advanced Micro Devices Stock Monday?

Leggett & Platt shares are trading lower after the company reported better-than-expected Q1 EPS results and raised its FY25 EPS guidance.

Crane (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) affirms FY2025 Adj EPS guidance from $5.30-$5.60 to $5.30-$5.60 vs $5.50 analyst estimate. sees sales of $2.238 billion vs $2.27 billion analyst estimate.

Crane Sees FY 2025 Sales $2.238B vs $2.27B Est

Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.54) by 22.22 percent. This is a 65.57 percent increase over losses of $(1.22) per share from the same period last year. The company reported quarterly sales of $231.75 million which missed the analyst consensus estimate of $288.15 million by 19.57 percent. This is a 39.38 percent decrease over sales of $382.28 million the same period last year.

Beyond Q1 Adj. EPS $(0.42) Beats $(0.54) Estimate, Sales $231.75M Miss $288.15M Estimate

Press Releases

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development

Health Care

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

Actuate Therapeutics to be Added to Russell 2000® Index

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

General

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025

Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Comments

Actuate Therapeutics

Noticias

Últimas noticias sobre Actuate Therapeutics (NASDAQ:ACTU) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL